Forsight Vision4, Inc.

Nexisvision, Inc.

Baxter International Inc.

Baxter Healthcare Sa

Mati Therapeutics Inc.

Azura Ophthalmics Ltd.

Forsight Vision6, Inc.

The Foundry, Inc.

Other

Fusion Medical Technologies, Inc.

Novartis Ag

Surmodics, Inc.

Transcend Medical, Inc.

Qlt Inc.

Baxter Healthcare Inc.

Cary J Reich

Eugene De Juan, Jr

Yair Alster

K Angela Macfarlane

Stephen A Boyd

Jose D Alejandro

Douglas Sutton

Kathleen Cogan Farinas

Matt Clarke

Randolph E Campbell

Brian Levy

Hanson S Gifford, Iii

Mark E Deem

Kuangmon Ashley Tuan

A Edward Osawa

Signe R Erickson

Felix Vega

Raymond Lum

Doron Friedman

Shimon Amselem

Omer Rafaeli

Alan R Rapacki

David Sierra

Ashley Tuan

Dean F Carson

Michael Barrett

Doug Rimer

Enrique Barragan

Hanson Gifford

Darren G Doud

Eugene De Juan

Steven M Chamow

Donald G Wallace

Andreas Goessl

Atsushi Edward Osawa

Narinder S Shargill

Zhen Qian

Kirsten Angela Macfarlane

Robert George

Christina Skieller

David Batten

Mike Barrett

Greg Stine

K Angela MacFarlane

Janelle Chang

John H Morriss

Russell J Redmond

John Anthony Scholl

Matthew Clarke

Guy Oren

Alexander J Gould

Claude A Vidal

Woonza M Rhee

Richard L Lindstrom

Robert E Nordquist

Blaine Bueche

Zhen Qian-Wallis

Jean Toner-Webb

Michael Lerner

David Gibson

Christopher V Cardenas

Anne Brody Rubin

Tommy Jewell

Lorrie Ma

Tuan Anh Nguyen

Michael Collinson

Deepank Utkhede

Rachna Jain

Robert W Shimizu

Helen Tran

Paul DeAntonio

Stephen L Coulter

Omer Refaeli

Ravi Srinivasan

Joseph F Rondinone

Hanson G Gifford, Iii

Carlos Schuler

Jeffrey Forsberg

Harold Levy

William J Bertrand

Logan Stark

Angela K MacFarlane

Angela MacFarlane

Ngoc-Tuan Nguyen

Matt Clark

Kunagmon Ashley Tuan

Hanson S Giffor, Iii

Hanson S Gifford Iii

Eugene De Juan Jr

Hanson S Gifford

Stephen Boyd

Alexander Julian Gould

Jr Eugene De Juan

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Compositions and methods for the treatment of meibomian gland dysfunction

An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Nasolacrimal drainage system implants for drug therapy

Described is a process for making a dry and stable hemostatic composition, said process comprising

Process for making dry and stable hemostatic compositions

Disclosed is an accommodating intraocular lens device for treatment of an eye including a stabilization haptic () configured to be positioned within a region of an eye and a lens body having a sealed chamber containing a fixed volume of optical fluid. The lens body includes a shape changing membrane () configured to outwardly bow in a region surrounding the optical axis of the eye; a shape deformation membrane configured to undergo displacement relative to the first shape changing membrane; and a static element (). An inner surface of the shape changing membrane, an inner surface of the shape deformation membrane and an inner surface of the static element collectively form the sealed chamber. The lens device also includes a force translation arm () having a first end configured to contact an outer surface of the shape deformation membrane of the lens body and a second end configured to engage a ciliary structure of the eye. The force translation arm is configured to move relative to the lens body upon movement of the ciliary structure.

Accommodating intraocular lens

Ophthalmic lenses for correcting refractive error of an eye are disclosed. Ophthalmic lenses include a deformable inner portion and a deformable peripheral portion. When disposed over the optical region of an eye, the inner portion is configured so that engagement of the posterior surface against the eye deforms the posterior surface so that the posterior surface has a shape diverging form the refractive shape of the epithelium when viewing with the eye through the ophthalmic lens. The rigidity of the inner portion is greater than the rigidity of the peripheral portion and the ophthalmic lenses are configured to allow movement relative to the eye upon blinking of the eye and to be substantially centered on the optical region of the cornea following the blinking of the eye. Methods of correcting refractive errors of an eye such as astigmatism or spherical aberration using the ophthalmic lenses are also disclosed.

Contact lenses for refractive correction

Described herein are intraocular lenses and methods of implantation. In one aspect, the lens includes a shape changing optical element; a force translation element having a first end region coupled to the optical element and a second end region extending towards a ciliary structure, and an attachment portion coupled to the second end region of the force translation element and configured to contact the ciliary structure. The force translation element is configured to functionally transmit movements of the ciliary structure into a force exerted upon the optical element to effect an accommodating and a disaccommodating change of the optical element.

Intraocular accommodating lens and methods of use

An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.

Diagnostic methods and apparatus

Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.

Injector apparatus and method for drug delivery

Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.

Combined drug delivery methods and apparatus

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Posterior segment drug delivery

An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.

Drug delivery methods, structures, and compositions for nasolacrimal system

Growing community of inventors

Menlo Park, CA, United States of America

Cary J Reich